Evidence map›Paper›PMID 37215143›Full record

ArticleFrontiers in immunology2023

Evaluation of triple negative breast cancer with heterogeneous immune infiltration.

Ángela Quintana, Enrique Javier Arenas, Cristina Bernadó, José Fernández Navarro, Jonatan González, Anna Esteve-Codina, Teresa Moliné, Merce Marti, Giuseppe Curigliano, Peter Schmid and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ángela QuintanaBreast Cancer Unit, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
Enrique Javier ArenasPreclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Cristina BernadóPreclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
José Fernández NavarroBioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
Jonatan GonzálezBioinformatics Department, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.
Anna Esteve-CodinaCNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Teresa MolinéDepartment of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
Merce MartiDepartament Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS, Milan, Italy.
Peter SchmidBarts Cancer Institute, Queen Mary University London, London, United Kingdom.
Vicente PegBiomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
Joaquín ArribasPreclinical Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Javier CortésBreast Cancer Unit, Vall d'Hebrón Institute of Oncology, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in the clinical setting as a continuous variable, without a clear defined cut-off. However, there are scenarios where the immune infiltration is heterogeneous that some areas of the patient's tumour have high numbers of TILs while other areas completely lack them. This spontaneous presentation of a heterogeneous immune infiltration could be a great opportunity to study why some tumours present TILs at diagnosis but others do not, while eliminating inter patient's differences. Methods: In this study, we have identified five TNBC patients that showed great TIL heterogeneity, with areas of low (≤5%) and high (≥50%) numbers of TILs in their surgical specimens. To evaluate immune infiltration heterogeneity, we performed and analyzed bulk RNA-sequencing in three independent triplicates from the high and low TIL areas of each patient. Results: Gene expression was homogeneous within the triplicates in each area but was remarkable different between TILs regions. These differences were not only due to the presence of TILs as there were other non-inflammatory genes and pathways differentially expressed between the two areas. Discussion: This highlights the importance of intratumour heterogeneity driving the immune infiltration, and not patient's characteristics like the HLA phenotype, germline DNA or immune repertoire.

Indexed as

Triple Negative Breast NeoplasmsBiomarkers, TumorHumansLymphocytes, Tumor-InfiltratingPrognosisBiomarkers, Tumorimmune cell abundanceintratumor heterogeneitytranscriptomicstriple negative breast cancertumor-infiltrating lymphocytes

Identifiers

PMID37215143
PMCPMC10196631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.